Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 13Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 7Neoplasm Metastasis 6Melanoma 5Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Solid Tumor 2Recurrence 2Prostatic Neoplasms 2Lung Neoplasms 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Carcinoma 2Advanced Solid Tumor 2Advanced Malignancies 2cMET-dysregulated Advanced Solid Tumors 1Urothelial Cancer 1Thyroid Neoplasms 1Synovitis, Pigmented Villonodular 1Solid Tumours 1Solid Tumour 1Solid Tumors, KRAS Mutation 1Solid Tumors 1Solid Tumor, Adult 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Prostate Cancer Patients 1

Interventions

LY3295668 erbumine 3Topotecan 1TAS-119 1Paclitaxel 1Midazolam 1Cyclophosphamide 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Epilepsy × Midazolam × Clear all
NCT03955939 2020-06-01

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Eli Lilly and Company

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡